Achema middle east

Indian Government to come out with a new pharma policy

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Modular and Portable Laboratory Equipment Supporting Flexible Pharma Operations

Modern pharmaceutical manufacturing demands adaptable infrastructure capable of rapid reconfiguration to accommodate changing production requirements, making modular and portable laboratory equipment essential for contract manufacturers, clinical trial operations, and organizations pursuing capacity expansion through scalable platform technologies.

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.

Smarter Resource Planning for Complex Pharma Development Portfolios

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.
- Advertisement -

The government is looking to bring in a new pharma policy for implementing the proposed healthcare plan across the country in the next couple of months, Union Chemicals and Fertilisers Minister Ananth Kumar said today.

“We are eliciting opinions, we are having discussions and new dimension has been added in this budget of universal healthcare that also has to be co-opted into this pharma policy. In couple of months we will finalize it,” Kumar said.

While doing so, we will go for all-round reforms so that ease of doing business and ease of living can go hand in hand, he added.

The big healthcare initiative announced in the budget for 2018-19 seeks to cover 10 crore households requires many verticals — infrastructure, human resources and pharma and medical device products, Kumar told reporters here.

To fulfill this huge demand we have urged the participants of the conclave to ensure implementation of healthcare initiative through ‘Make in India’ efforts. The moto of the prime minister is to provide quality and affordable healthcare, he added.

“My estimation is that this decision of the Prime Minister will lead to India becoming number one pharmacy in the world in five years,” Kumar said.

“We are for a reform of regulatory rules and regulations governing pharma and medical devices without compromising on quality and affordability. These are the touch stones for pharma and medical devices by the government of India,”he said.

Pharma and Medical Devices sector will be a major employment provider going forward, he added.

“We have global presence and supply pharmaceutical to more than 215 countries and are the third biggest manufacturers. Compared to global growth rate of 5 per cent we are growing at the rate of 15 per cent,” Kumar said.

When asked if the government was also mulling fixing prices of other medical devices, he said: “There is huge demand from the people that various other implants and devices should be under price control and the government is seriously considering it.”

The minister also said the country needs a separate ministry of pharma and medical devices. “I have been pursuing this. My ministry is pursuing this with the Prime Minister,” Kumar said.

Latest stories

Related stories

Modular and Portable Laboratory Equipment Supporting Flexible Pharma Operations

Modern pharmaceutical manufacturing demands adaptable infrastructure capable of rapid reconfiguration to accommodate changing production requirements, making modular and portable laboratory equipment essential for contract manufacturers, clinical trial operations, and organizations pursuing capacity expansion through scalable platform technologies.

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.

Smarter Resource Planning for Complex Pharma Development Portfolios

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.

Aligning Scientific Innovation with Commercial Reality in Drug Development

The "Valley of Death" in pharma is no longer just about scientific failure; it is about commercial irrelevance. This article examines the critical need to align R&D ambition with market reality early in development. It explores the evolution of the Target Product Profile (TPP) into the Target Value Profile (TVP), the role of the "commercial scientist," and strategies for integrated evidence generation that satisfy both regulators and payers.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »